X0306
4
2019-06-24
0
0001744659
Akero Therapeutics, Inc.
AKRO
0001404955
Harrison Seth Loring
C/O AKERO THERAPEUTICS, INC.
170 HARBOR WAY, 3RD FLOOR
SOUTH SAN FRANCISCO
CA
94080
1
0
1
0
Common Stock
2019-06-24
4
C
0
4228764
A
4228764
I
See Footnote
Common Stock
2019-06-24
4
C
0
286439
A
4515203
I
See Footnote
Common Stock
2019-06-24
4
P
0
900000
16
A
5415203
I
See Footnote
Series A Preferred Stock
2019-06-24
4
C
0
13000000
0
D
Common Stock
4228764
0
I
See Footnote
Series B Preferred Stock
2019-06-24
4
C
0
880568
0
D
Common Stock
286439
0
I
See Footnote
Represents the total number of shares of common stock received by Apple Tree Partners IV, L.P. ("ATP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.
Represents the total number of shares of common stock received by ATP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
These shares are owned directly by ATP. The Reporting Person is a principal of the general partner of ATP and disclaims beneficial ownership of the shares held by ATP, except to the extent of his pecuniary interest therein. The Reporting Person has sole voting and investment control and power over the shares held by ATP.
On June 24, 2019, ATP purchased 900,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering.
/s/ Jonathan Young, as attorney-in-fact
2019-06-25